| Class | Antiparkinsonian agent |
|---|---|
| Chemistry |
Nitrocatechol |
| Routes of administration |
oral |
| Absorption |
Oral bioavailability 35% |
| Solubility |
pKa = 4.5, practically insoluble in water |
| Distribution |
VOD= 0.3L/kg, 98% protein-bound |
| Metabolism |
hepatic metabolism - primarily metabolised to its glucuronide |
| Elimination |
Minimal free drug is eliminated in the urine |
| Time course of action |
Half-life 1.-0-2.5 hours |
| Target receptor |
Catechol-O-methyl transferase (which it inihibits) |
| Mechanism of action |
By inhibiting COMT, entecapone prevents the peripheral metabolism of L-dopa, and is an adjunct to LD and a peripherally acting dopa decarboxylase inhibitor. It has no antiParkinsonian activity of its own. |
| Clinical effects |
Apart from its desiable effecst 9proloning the effects of levodopa), entacapone can increase dyskineasias, and produce diarrhoea. Hypertension is not usually seen unless there is sufficient noradrenaline or adrenaline being released for some other reason. Also it can turn your urine black or brown. |
| Literature reference |
Habet, 2022 |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |